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Fundamental management is required soon after a diagnosis of acute pancreatitis 
has been made and includes monitoring of the conscious state, the respiratory and 
cardiovascular system, the urinary output, adequate fluid replacement and pain control, 
blood purification therapy and nutritional support. An adequate dose of fluid replacement 
is essential to stabilize cardiovascular dynamics and the dose should be adjusted while 
assessing circulatory dynamics constantly. Current clinical practice guidelines 
recommend aggressive fluid resuscitation despite limited prospective data. Fluid therapy 
remains the mainstay of early management of patients with acute pancreatitis and 
severe acute pancreatitis. High-level evidence is lacking to guide protocols for fluid 
resuscitation in patients presenting with acute pancreatitis. In those patients with severe 
acute pancreatitis, the available evidence indicates that controlled fluid resuscitation 
with crystalloids and colloids offers the best outcome. Hematocrit remains a useful 
marker to guide fluid resuscitation in acute pancreatitis. However, the timing and ideal 
“cut-off” level needs to be determined. Acta Medica Medianae 2013;52(3):55-60. 
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Introduction 
 
Acute pancreatitis is potentially a fatal disease 
and its mortality rate is 2.1–7.8%. In 10–20% of 
patients with acute pancreatitis, the disease 
becomes severe and the mortality rate associated 
with acute pancreatitis increases up to 14–25% if 
the disease is aggravated (1). The prognosis of 
acute pancreatitis is determined by two factors 
including organ failure and pancreatic necrosis.  
Patients with a diagnosis of acute pancrea-
titis should be hospitalized. Initial treatment 
should be started as soon as possible. Adequate 
respiratory and cardiovascular monitoring is crucial 
involving the conscious state, temperature, pulse 
rate, blood pressure, urinary output, respiratory 
frequency, and oxygen saturation. Initial treatment 
and adequate monitoring should be continued 
while patients are being transferred from the 
emergency room to a sick ward and from a clinic 
to a general hospital. Initial treatment includes 
fasting, adequate dose of fluid replacement and 
sufficient pain relief.  
Along with the etiologic diagnosis of acute 
pancreatitis, severity assessment of acute pancrea-
titis should be conducted based on the severity 
scoring system of acute pancreatitis of the 
Japanese Ministry of Health, Labour, and Welfare 
(2008).  
Acute pancreatitis can become severe even 
if it is mild at the initial visit of a patient, so 
repeated severity assessment is crucial. Strict respi-
ratory and cardiovascular management is required 
in patients with a diagnosis of severe acute 
pancreatitis, so transference to a medical facility 
should be considered where intensive care, 
interventional treatment, blood purification therapy 
and nutritional support are available. Prophylactic 
antibiotic administration is recommended for severe 
acute pancreatitis. There is no consensus on the 
usefulness of protease inhibitors. Enteral nutrition 
initiated in the early phase of the disease is 
superior to intravenous hyperalimentation. 
 
What are the parameters for adequate 
dose of fluid replacement as the initial 
treatment of acute pancreatitis? 
 
Initial fluid replacement should be performed 
to secure, as its target, stable cardiovascular 
dynamics with an average blood pressure of 
more than 65 mmHg as their parameters and the 
urinary output of 0.5–1 ml/kg/h.  
In acute pancreatitis, increased vascular 
permeability and decreased colloid osmotic 
pressure give rise to a leakage of extracellular fluid  
into the peripancreas, the retroperitoneum as well 
as into the abdominal and thoracic cavities, which 
results in a loss of a large volume of the circulating 
plasma. Acute cardiovascular disorders brought Volume therapy in acute pancreatitis                                                                                                            Biljana Stošić et al. 
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about in this manner are one of the causes of 
aggravated initial condition of acute pancreatitis. 
Therefore, it is mandatory to stabilize the cardio-
vascular dynamics mainly through replacing a 
sufficient dose of extracellular fluid initiated in 
the early phase of the disease. Calcium and 
potassium chloride should be replaced if deficiencies 
arise. Hyperglycemia is managed with insulin as 
needed.  
In patients with severe acute pancreatitis, 
continuous monitoring of central venous pressure 
or pulmonary wedge pressure, blood gas analysis, 
and electrolyte measurement is crucial to 
determining the adequate volume that must be 
replaced. Oxygen is administered as needed to 
maintain at least 95% of oxygen saturation. A 
recent report has shown that excessive fluid 
replacement that has been conducted rapidly and 
continuously for a long time despite the presence 
of acute pancreatitis has adverse effects on the 
prognosis (2). When the initial treatment is 
delivered, repeated assessment of the cardio-
vascular dynamics should be conducted. Imme-
diately after the start of treatment in particular, 
the assessment should be conducted every 4–6h 
and the transfusion speed should be adjusted so 
that an adequate dose of fluid can be achieved. 
Given the lack of an effective pharmacologic 
treatment, attention has focused on optimizing 
supportive measures. In particular, data from 
experimental animal models of acute pancreatitis 
suggest that vigorous fluid resuscitation may 
enhance the pancreatic microcirculation (3). The 
notion that more aggressive fluid resuscitation 
could potentially prevent necrosis was further 
advanced by indirect evidence from a small 
retrospective study that indicated nearly all 
patients with hemoconcentration on admission 
(hematocrit >44%) who did not experience a 
decrease in hematocrit during the first 24h of 
hospitalization went on to develop pancreatic 
necrosis. On the basis of this limited evidence, 
nearly all current clinical practice guidelines 
recommend vigorous fluid resuscitation for initial 
treatment of acute pancreatitis. In issue of the 
American Journal of Gastroenterology, Enrique de-
Madaria et al. present findings from a prospective 
observational cohort study designed to evaluate 
the impact of early fluid resuscitation on clinical 
outcomes in patients with acute pancreatitis (4).  
Early fluid resuscitation was defined as the 
volume of fluid administered during the initial 
24h of hospitalization. The study investigators 
classified resuscitation volumes according to 
quartiles as low (lowest quartile), moderate 
(second and third quartile), and high (highest 
quartile). Specific outcomes measured included 
persistent organ failure (>48h, primary outcome) 
and local complications as well as mortality as 
secondary end points. 
The study presents several interesting 
findings. First, the majority of patients received 
between 3 and 5l of fluid during the initial 24 h of 
hospitalization. Next, at least according to the 
current treatment recommendations, patients in 
the lowest quartile of fluid resuscitation (<3.1l) 
may have been arguably under-resuscitated. 
Nevertheless, there was no excess in local 
complications, organ failure, or mortality among 
this group of patients. By contrast, patients who 
received the highest volumes of fluid (>4.1l) 
experienced a significant increase in the rate of 
persistent organ failure and local fluid collections. 
This association persisted after adjusting for 
several potential confounders including age, 
Charlson comorbidity score, body mass index, 
and systemic inflammatory response syndrome 
status.  
Each patient’s actual fluid resuscitation 
parameters were based on clinician judgment, 
which complicates the interpretation of the study 
findings. In particular, although increased fluid 
resuscitation was associated with numerous 
complications, it is not possible to infer causation 
based on the present study design. The reverse 
may be true such that patients with more severe 
illness would receive greater fluid resuscitation by 
their treating physician.  
The present findings call into question 
several long held beliefs regarding fluid resusci-
tation in acute pancreatitis. First, it appears clear 
that not all patients require or benefit from 
“aggressive” fluid resuscitation. Second, there did 
not appear to be a benefit to administration of 
large volume resuscitation (>4l) during the first 
24h of hospitalization. This latter finding is 
consistent with a recent randomized-controlled 
trial conducted in China, in which patients with 
acute pancreatitis who had evidence of hemo-
concentration (hematocrit >44%) at admission 
were assigned to either an aggressive resusci-
tation strategy or a more conservative approach 
(5). In the aggressive resuscitation arm, fluids 
were administered to achieve a hematocrit of 
35% or less within 48h. As expected, patients 
assigned to the aggressive treatment arm 
received greater fluids compared with the more 
conservative treatment group (mean 4.8 vs. 3.8l, 
respectively, P=0.005). However, patients in the 
aggressive treatment group experienced greater 
frequency of sepsis and higher mortality during 
hospitalization. Similarly, patients who received 
>4l of fluid during the first 24h of hospitalization 
were noted to have increased frequency of 
respiratory complications in a retrospective cohort 
study from Sweden (6).   
Besides the volume of fluid resuscitation, 
recent attention has also focused on the manner 
in which fluid resuscitation is delivered. Several 
recent retrospective studies have suggested that 
the proportion of fluid administered in the initial 
phase of acute pancreatitis may be more 
important than the total aggregate volume (7). 
In the present study by de-Madaria et al., it 
would have been helpful to know the rate at 
which fluids were administered, e.g., as bolus or 
continuous infusion. It is possible, for example, Acta Medica Medianae 2013, Vol.52(3)                                                                                Volume therapy in acute pancreatitis 
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that an approach similar to that advocated for 
septic shock may prove useful in acute pancrea-
titis. Current recommendations in septic shock 
are to administer an initial volume challenge to 
determine whether a patient’s condition is fluid 
responsive rather than providing ongoing high-
volume fluid administration at a continuous rate 
(8). 
There is a need to review the data on fluid 
resuscitation in acute pancreatitis to aid the 
development of evidence-based guidelines. All 
available major publications from the past 45 
years were considered and a total of 12 studies 
were identified describing regimens for fluid 
therapy. These included 2 randomized controlled 
trials, 1 retrospective cohort study, and 9 reviews. 
 
 
Rationale for Fluids in Acute Pancreatitis  
 
The impact of retroperitoneal fluid losses 
and dehydration on the development of hypo-
volemia seen in patients with severe acute 
pancreatitis resulting in high mortality was 
recognized in the 1950s (9). This fluid loss was 
largely shown to respond to intravenous fluid 
therapy, the initial understanding was that the 
shock was mainly due to a loss of red blood cells 
(10). Thereafter, despite the link between hemo-
concentration at admission and mortality in acute 
pancreatitis being suggested by Davis et al. and 
Gray et al., a reduction in hematocrit in the first 
48 hours was considered a poor risk factor in 
acute pancreatitis as evidence by the scoring 
system proposed by Ranson et al. (11-13). 
 
Table 1.Summary of the available studies to date on fluid therapy in acute pancreatitis 
 
Author, 
Year, Type of study 
(sample size) 
Conclusion 
Level of 
evidence 
Mao et al. (26) 
2010 RCT (n=155) 
Rapid hemodilution increases incidence of sepsis within 28 days and 
in-hospital mortality 
 HCT should be maintained between 30% and 40% in acute response 
stage 
I 
Mao et al. (27) 
2009 RCT (n=76) 
Controlled fluid resuscitation offers better prognosis in patients with 
severe volume deficit within 72 h of severe acute pancreatitis onset 
I 
Gardner et al. (20) 2009 
Retrospective cohort (n=45) 
Patients with severe acute pancreatitis should receive 1/3 or more of 
initial 72 h cumulative i.v. fluid volume during first 24 h 
III 
Pezzilli et al. (23) 
2010 Review 
Prompt adequate i.v. fluid administration to correct volume deficit and 
maintain basal fluid requirements 
- 
Forsmark et al. (19) 
2007 Review 
Target: urine output 0.5 mL/kg body weight/h or more 
Crystalloids: preferred  
Indications for colloids:  
Packed red blood cells, when HCT falls less than 25%  
Albumin: serum albumin level drops to 2 g/dL 
Precautions: evidence of cardiovascular system dysfunction or 
pulmonary capillary leak syndrome 
Central venous pressure or pulmonary artery catheter indicated in 
severe acute pancreatitis 
V 
Otsuki et al. (21) 
2006 Review 
Ringer’s lactate: 60-160 mL/kg body weight/day  
About 1/3-1/2 of amount required for first 24 h, within the first 6 h  
Hourly: pulse, blood pressure, urine output, central venous pressure 
monitoring  
V 
Pandol et al. (22) 
2007 Review 
Severe volume depletion: 500-1,000 mL/h for several hours with 
amount of fluid reduced, once signs of severe volume depletion have 
subsided non pancreatic fluid loss: 300-500 mL/h  
No clinical volume depletion: 250-300 mL/h  
Fluid rates reassessed 1-2 hourly in severely depleted patients or at 
least 4 hourly for other patients 
V 
Banks et al. (18) 
2006 Review 
Aggressive i.v. fluid replacement Aggressive hydration (e.g. a bolus of 
fluids to achieve hemodynamic stability, followed by 250-500 mL/h 
crystalloids in an average sized patient without substantial kidney or 
heart disease  
V 
Whitcomb et al. (28) 
2006 Review 
Intravenous hydration 250-300 mL/h or more for 48 h   V 
Tenner et al. (24) 
2004 Review 
Aggressive i.v. fluid replacement   V 
Vege et al. (25) 
2004 Review 
After initial rapid resuscitation, fluid replacement should aim at 35 
mL/kg body weight/day  
V 
Wilmer et al. (29) 
2004 Review 
Crystalloids: preferred  V 
HCT: hematocrit; RCT: randomized controlled trial  
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Ranson et al. attributed the low hematocrit 
to pre-existing anemia encountered in alcoholics, 
while Trapnell found the fall in hematocrit to 
correlate with internal hemorrhage (14). The 
early use of fluid therapy has certainly reduced 
early mortality in acute pancreatitis associated 
with hypovolemia.  
In the 1990s, the importance of hemo-
concentration was re-visited by the group from 
the Brigham and Women’s Hospital in Boston 
(15, 16). Since then, hemoconcentration based 
on a serum hematocrit level at admission has 
been consistently demonstrated to be linked to 
the development of pancreatic necrosis (17). 
Pancreatic microcirculation depends on circulating 
volume and responds poorly to other influences. 
 
Available Evidence on Regimens for Fluid 
Therapy in Acute Pancreatitis 
  
-  Human Studies - Table 1 lists the articles/ 
studies involving fluids in acute pancreatitis, their 
conclusions, as well as, the level of evidence (18 
-30). 
-  Animal Studies - Animal studies conducted 
over the last four decades in the context of aiding 
the decision on the choice of fluid in the clinical 
setting have not been particularly helpful (31). 
 
Based on the review of literature we can 
conclude that hemoconcentration in a patient 
with acute pancreatitis (based on serial measure-
ments of hematocrit) within the first 48 hours of 
admission is a marker of poor prognosis and 
indicates the need for fluid resuscitation. The 
ideal cut-off level for serum hematocrit (44% or 
47%) remains to be determined. What can also 
be concluded from the available literature is that 
fluid therapy remains the cornerstone in the early 
management of acute pancreatitis and especially 
in the prevention of severe acute pancreatitis. In 
patients who go on to develop severe acute 
pancreatitis either due to a late presentation or 
despite resuscitation, fluid therapy has the potential 
to reduce the progression of pancreatic necrosis 
and its associated risk of mortality.  
In 2008, Gardner et al. reviewed the available 
evidence on fluid resuscitation in acute pan-
creatitis and found that there was a paucity of 
evidence to support clinical recommendations at 
that time (32). To date, there continues to be a 
lack of high-level evidence to guide the ideal 
“initial” fluid strategy for all patients presenting 
with acute pancreatitis in terms of choice of fluid, 
namely crystalloids and/or colloids, and if 
crystalloids, Ringer’s lactate or normal saline, as 
well as in terms of rate of administration. While 
crystalloids appear to be the ideal choice based 
on expert opinion and the guidelines/ recommen-
dations from America, Italy and Japan, these 
recommendations are not based on high-level 
evidence in patients with acute pancreatitis (18, 
19, 21-25, 28, 29). In patients with severe acute 
pancreatitis, the two randomized trials available 
used a combination of crystalloids and colloids, and 
favoured controlled resuscitation over rapid infusion 
within the first 72 hours (26, 27). Considering that 
both of these trials were performed by the same 
group, these results need to be validated by 
other groups. There has been no further impetus 
even in animal studies since the last major 
review by Gardner et al. (32). 
 
Conclusion 
 
Fluid therapy remains the mainstay of early 
management of patients with acute pancreatitis and 
severe acute pancreatitis. High-level evidence is 
lacking to guide protocols for fluid resuscitation in 
patients presenting with acute pancreatitis. In those 
patients with severe acute pancreatitis, the 
available evidence indicates that controlled fluid 
resuscitation with crystalloids and colloids offers the 
best outcome. Hematocrit remains a useful marker 
to guide fluid resuscitation in acute pancreatitis. 
However, the timing and ideal “cut-off” level need 
to be determined. 
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TERAPIJA TEČNOSTIMA KOD AKUTNOG PANKREATITISA 
 
Biljana Stošić, Radmilo Janković, Danijela Stanković, Ines Veselinović 
 
 
Neposredno nakon postavljanja dijagnoze akutnog pankreatitisa, neophodan je 
suštinski terapijski tretman, što uključuje monitoring stanja svesti, respiratornog i 
kardiovaskularnog sistema, diureze, adekvatnu nadoknadu volumena tečnostima, kontrolu 
bola, purifikacionu terapiju krvi i nutricionu potporu. Adekvatna količina nadoknade fluida je 
esencijalna za stabilizaciju kardiovaskularne dinamike, a količina se prilagođava dok se ne 
postigne stabilnost i konstantnost cirkulatorne dinamike. Dosadašnji vodiči kliničke prakse 
preporučivali su agresivnu nadoknadu fluida, uprkos limitiranim prospektivnim podacima 
koji bi te preporuke potvrdili. Terapija fluidima ostaje kamen temeljac ranog tretmana 
bolesnika sa akutnim pankreatitisom i teškim akutnim pankreatitisom. Ne postoje precizni 
protokoli i klinički vodiči visokog nivoa tečnosti za rasuscitaciju bolesnika sa akutnim 
pankreatitisom. Kod bolesnika sa teškim akutnim pankreatitisom, dostupni podaci 
preporučuju kontrolisanu nadoknadu fluida, što omogućava najbolji oporavak bolesnika. 
Hematokrit ostaje koristan pokazatelj pri nadoknadi fluida u akutnom pankreatitisu. 
Međutim, vreme i idealna referentna vrednost tek treba da budu determinisani. Acta 
Medica Medianae 2013;52(3):55-60. 
 
Ključne reči: akutni pankreatitis, vodiči, reanimacija 
 
 